请输入您要查询的百科知识:

 

词条 Reata Pharmaceuticals
释义

  1. Pipeline

      Bardoxolone Methyl    RTA 408    Others  

  2. Partnerships

  3. References

  4. External links

{{Infobox company
| traded_as = {{NASDAQ|RETA}} (Class A)
Russell 2000 Component
}}Reata Pharmaceuticals, Inc. is a pharmaceutical company based in Irving, Texas. Founded in 2002, Reata is primarily focused on investigating experimental oral antioxidative and anti-inflammatory drugs,[1] which dually activate the antioxidative transcription factor Nrf2 and inhibit the pro-inflammatory transcription factor NF-κB.[2]

Pipeline

The antioxidative and anti-inflammatory compounds bardoxolone methyl and RTA 408 are the lead clinical development compounds in Reata’s portfolio.

Bardoxolone Methyl

Bardoxolone methyl was one of the first of the class of synthetic triterpenoids to be studied in the clinic. It has been evaluated in Phase 1 studies for cancer,[3] Phase 2 and 3 studies for chronic kidney disease (CKD) associated with type 2 diabetes,[4][5] and is currently being evaluated in a Phase 2 study for pulmonary arterial hypertension.[6][7][8]

RTA 408

Omaveloxolone (RTA 408) is a second generation member of the synthetic oleanane triterpenoid compounds and currently in clinical development. Preclinical studies have demonstrated that RTA 408 possesses antioxidative and anti-inflammatory activities,[9][10] as well as the potential to improve mitochondrial bioenergetics.[11] Because of the broad applicability of such effects across many diseases, RTA 408 is currently under clinical investigation in several Phase 2 clinical studies including immunooncology,[12] corneal endothelial cell loss associated with cataract surgery[13] Friedreich’s ataxia,[14] and mitochondrial myopathies.[15][16]

Others

Reata is also actively engaged in the discovery of small molecule disease-modifying drugs that function by stabilizing the normal three-dimensional structure of target proteins or generally enhancing the folding environment of the cell. Defects in protein folding underlie a large number of genetic diseases including certain forms of cancer, familial Alzheimer's disease, and cystic fibrosis. Protein folding defects are also believed to play important roles in the development of non-inherited forms of many of these diseases.

Partnerships

Reata has a licensing agreement with Kyowa Hakko Kirin for development and commercialization of bardoxolone methyl for CKD and related indications in Japan, China, Taiwan, Korea, and other select Southeast Asian countries.[17]

Reata also has a licensing agreement with Abbvie for development and commercialization of bardoxolone methyl outside the U.S., excluding Asian markets defined in the agreement with Kyowa Hakko Kirin.[18] Abbvie and Reata also have a second agreement for development of the second generation portfolio of synthetic oleanane triterpenoid compounds, including RTA 408, as well as other Nrf2 activators.[19]

References

1. ^{{cite web|title=Our Story|url=http://reatapharma.com/about-us/our-story/|website=Reata Pharmaceuticals|accessdate=5 August 2016}}
2. ^{{Cite journal|title = New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress|vauthors=Sporn MB, Liby KT, Yore MM |date = 2011|journal = J Nat Prod|doi = 10.1021/np100826q|pmid = 21309592|volume = 74|issue=3 |pages = 537–45|pmc=3064114|display-authors=etal}}
3. ^{{Cite journal|url = http://clincancerres.aacrjournals.org/content/18/12/3396.long|title = A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas|vauthors=Hong DS, Kurzrock R, Supko JG |date = 2012|journal = Clin Cancer Res|doi = 10.1158/1078-0432.CCR-11-2703|pmid = 22634319|volume = 18|issue = 12|pages = 3396–406|display-authors=etal|pmc=4494099}}
4. ^{{Cite journal|title = Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes|vauthors=Pergola PE, Raskin P, Toto RD |date = 2011|journal = N Engl J Med|doi = 10.1056/NEJMoa1105351|pmid = 21699484|pages = 327–36|volume = 365|issue = 4|display-authors=etal}}
5. ^{{Cite journal|title = Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease|vauthors=de Zeeuw D, Akizawa T, Audhya P |date = 2013|journal = N Engl J Med|doi = 10.1056/NEJMoa1306033|pmid = 24206459|pages = 2492–503|volume = 369|issue = 26|display-authors=etal|pmc=4496027}}
6. ^{{Cite news|url = http://pulmonaryhypertensionnews.com/2014/06/30/reata-begins-enrollment-pah-lariat-phase-2-study-examining-bardoxolone-methyl-treating-pulmonary-arterial-hypertension/|title = Reata Begins Enrollment For PAH – LARIAT Phase 2 Study Examining Bardoxolone Methyl for Treating Pulmonary Arterial Hypertension|date = |work = |accessdate = 6 October 2014}}
7. ^{{Cite news|url = http://clinicaltrials.gov/ct2/show/NCT02036970?term=bardoxolone&rank=4|title = Bardoxolone Methyl Evaluation in Patients With Pulmonary Arterial Hypertension (PAH) (LARIAT)|date = |work = |accessdate = 6 October 2014}}
8. ^{{Cite news|url = http://www.fiercebiotech.com/story/after-taste-disaster-reata-plans-comeback-bardoxolone/2014-07-09|title = After a taste of disaster, Reata plans a comeback for bardoxolone|last = Carroll|first = John|date = 6 October 2014|work = |accessdate = }}
9. ^{{Cite journal|title = Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin.|vauthors=Reisman SA, Lee CY, Meyer CJ |date = 2014|journal = Arch Dermatol Res|doi = 10.1007/s00403-013-1433-7|pmid = 24362512|pages = 447–57|volume = 306|issue = 5|display-authors=etal}}
10. ^{{Cite journal|title = Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis.|vauthors=Reisman SA, Lee CY, Meyer CJ |date = 2014|journal = Radiat Res|doi = 10.1667/RR13578.1|pmid = 24720753|pages = 512–20|volume = 181|issue = 5|display-authors=etal}}
11. ^{{Cite journal|title = Neuroprotective effect of Nrf2/ARE Activators, CDDO-ethylamide and CDDO-trifluoroethylamide in a Mouse Model of Amyotrophic Lateral Sclerosis|vauthors=Neymotin A, Calingasan NY, Wille E |date = 2011|journal = Free Radic Biol Med|doi = 10.1016/j.freeradbiomed.2011.03.027|pmid = 21457778|pages = 88–96|volume = 51|issue=1 |pmc=3109235|display-authors=etal}}
12. ^{{Cite web|url = http://clinicaltrials.gov/ct2/show/NCT02029729?term=reata&recr=Open&rank=2|title = RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma)|date = |accessdate = 6 October 2014|website = |publisher = }}
13. ^{{Cite web|url = https://clinicaltrials.gov/ct2/show/NCT02128113|title = RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD|date = April 15, 2015|accessdate = |website = |publisher = }}
14. ^{{Cite web|url = http://clinicaltrials.gov/ct2/show/NCT02255435?term=reata&recr=Open&rank=4|title = RTA 408 Capsules in Patients With Friedreich's Ataxia (MOXIe)|date = |accessdate = 6 October 2014|website = |publisher = }}
15. ^{{Cite web|url = http://clinicaltrials.gov/ct2/show/NCT02255422?term=reata&recr=Open&rank=5|title = RTA 408 Capsules in Patients With Mitochondrial Myopathy (MOTOR)|date = |accessdate = 6 October 2014|website = |publisher = }}
16. ^{{Cite web|url = http://www.marketwatch.com/story/reata-announces-the-initiation-of-phase-2-studies-examining-rta-408-for-the-treatment-of-friedreichs-ataxia-and-mitochondrial-myopathies-2014-09-30|title = Reata Announces the Initiation of Phase 2 Studies Examining RTA 408 for the Treatment of Friedreich's Ataxia and Mitochondrial Myopathies|date = |accessdate = 6 October 2014|website = |publisher = }}
17. ^{{Cite news|url = https://www.bloomberg.com/apps/news?pid=newsarchive&sid=a43aaS3QleNo|title = Reata Pharmaceuticals Licenses Chronic Kidney Disease Drug|date = |work = |accessdate = 6 October 2014}}
18. ^{{Cite news|url = http://www.fiercebiotech.com/press-releases/abbott-and-reata-pharmaceuticals-announce-agreement-develop-and-commercialize-bardoxo|title = Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl|date = |work = |accessdate = 6 October 2014}}
19. ^{{Cite news|url = http://www.fiercebiotech.com/story/abbott-bets-400m-mega-blockbuster-future-reata-program/2011-12-12|title = UPDATED: Abbott bets $400M on mega-blockbuster future for Reata program|last = Carroll|first = John|date = |work = |accessdate = 6 October 2014}}

External links

  • Official website

5 : Pharmaceutical companies of the United States|Pharmaceutical companies established in 2002|Companies based in Irving, Texas|Health care companies based in Texas|Companies listed on NASDAQ

随便看

 

开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。

 

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间:2024/9/23 8:18:52